Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06474533

Fluoroethyltyrosine for the Evaluation of Intracranial Neoplasm

This is a single center study investigating the use of Fluoroethyltyrosine (FET) in the detection of brain tumors. FET accumulates in malignant cells within intracranial neoplasms and can be used to detect recurrent disease and characterize grade of glial neoplasms.

Recruiting

Interested in participating?

Request Info

Key information

Age range

4 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

University of California, San Francisco

San Francisco, California, 94143, United States

Location status: Recruiting

Location contact

Javier Villanueva-Meyer, MD

PRINCIPAL_INVESTIGATOR

Louise Magat

CONTACT

[email protected]

415-502-1822

Thomas Hope, MD

SUB_INVESTIGATOR

CONTACT

[email protected]

(887) 827-3222

About this study

PRIMARY OBJECTIVES:

  • To determine if FET Positron Emission Tomography (PET) scan can differentiate between benign treatment-related changes and recurrence in comparison to pathology in population 1 with recurrent metastatic disease and high-grade gliomas.
  • To determine if FET PET scan can differentiate between low-grade and high-grade gliomas in population 2.

SECONDARY OBJECTIVES:

  • To determine if FET PET scan can differentiate between benign treatment- related changes and recurrence in comparison to pathology or imaging follow-up in population 1.
  • To determine if FET PET scan can differentiate between benign treatment- related changes and recurrence in comparison to pathology in population 1 with recurrent low-grade gliomas.

EXPLORATORY OBJECTIVES:

  • To assess relationships between serial FET PET scan and clinical outcome in population 1 with recurrent metastatic disease and gliomas.

OUTLINE:

Participants will receive a single PET scan lasting for about 40 minutes in an outpatient setting after an injection with FET. Adult participants may undergo up to two repeat FET PET scans. Adverse events will be recorded.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Presence or suspicion of intracranial neoplasm in two populations:
  • Population 1: Participants after primary treatment (radiation therapy and/or surgery) with suspicion of recurrence on MRI.
  • Three sub-populations will be considered:
  • Recurrent metastatic lesions.
  • Recurrent high-grade gliomas (Grades 3 and 4).
  • Recurrent low-grade gliomas (Grade 2).
  • Population 2: Participants prior to primary treatment with planned biopsy or surgical resection.
  • Age > 3 years.

Participants in other clinical trials will be eligible for this study including patients undergoing surgery guided by 5-aminolevulinic acid.

Exclusion criteria

  • Participants with known incompatibility to PET or Computerized tomography (CT)/magnetic resonance imaging (MRI) scans.
  • Participants unlikely to comply with study procedures, restrictions and requirements and judged by the Investigator to be unsuitable for study participation.
  • Sedation or anesthesia can be used for participants who cannot tolerate the exam.

Treatment and study plan

Fluorethyltyrosine (18-F)

Drug

Given intravenously (IV)

Other names: Fluoroethyltyrosine (FET), FET, O-(2-[18F]fluoroethyl)-L-tyrosine (FET)

Positron Emission Tomography (PET)

Procedure

Undergo Imaging Procedure

Other names: PET scan, PET

Primary outcomes

  1. Maximum Intracranial lesion tumor-to-background ratio (TBRmax)

    Time frame: Up to 3 years

    The maximum TBR (TBRmax) will be calculated by dividing the SUVmean of the 1.6 centimeter (cm) diameter circular region of interest (ROI) by the mean standardized uptake value (SUVmean) of background normal tissue.

  2. Percentage of accurate prediction of presence of tumor (Population 1)

    Time frame: Up to 3 years

    The percentage of radiological read responses that accurately predict the presence of recurrent tumor in patients previously treated with surgery and/or radiation for population 1, broken down by metastatic disease, high-grade gliomas and low-grade gliomas will be reported

  3. Percentage of radiological read responses

    Time frame: Up to 3 years

    The percentage of radiological reads with a binary characterization of scan study as positive for recurrence disease in population 1, and positive for high-grade glial neoplasm in population 2 will be reported.

Study contacts

Contact information is provided by the study sponsor or research team.

Louise Magat

CONTACT

[email protected]

(415) 502-1822

Sponsors and collaborators

Lead sponsor

Thomas Hope

Other

Registry information

Important dates

Study start
2024
Primary completion
2028
Study completion
2028
First posted
Jun 25, 2024
Registry last updated
Apr 3, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.